Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCXNASDAQ:HYPRNASDAQ:LYRANASDAQ:SURG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$2.27-6.6%$1.53$0.17▼$1.99$4.13M0.514.05 million shs43,788 shsHYPRHyperfine$0.70-0.1%$0.70$0.53▼$1.90$54.51M0.95897,724 shs214,238 shsLYRALyra Therapeutics$10.68+3.9%$8.12$3.81▼$37.50$13.62M-0.01187,997 shs116,783 shsSURGSurgePays$2.81+4.5%$2.80$1.05▼$3.52$54.91M0.43633,398 shs96,438 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell-6.58%-15.30%-24.33%+992.92%+36.75%HYPRHyperfine-0.16%-16.15%+11.78%-18.92%-15.76%LYRALyra Therapeutics+3.89%-20.89%+99.81%+28.21%-17.47%SURGSurgePays+4.46%+5.64%-3.44%+108.15%-20.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AHYPRHyperfine2.2869 of 5 stars3.33.00.00.00.62.50.6LYRALyra Therapeutics3.1176 of 5 stars3.24.00.00.03.91.70.6SURGSurgePays3.1284 of 5 stars3.55.00.00.01.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/AHYPRHyperfine 2.67Moderate Buy$1.0651.60% UpsideLYRALyra Therapeutics 2.33Hold$100.00836.33% UpsideSURGSurgePays 3.00Buy$9.00220.28% UpsideCurrent Analyst Ratings BreakdownLatest LYRA, HYPR, SURG, and CTCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025SURGSurgePaysAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.75 ➝ $9.006/3/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/15/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/14/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.29 ➝ $0.684/22/2025SURGSurgePaysAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.50 ➝ $8.753/24/2025HYPRHyperfineLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$1.503/20/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.50 ➝ $1.20(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K1,445.06N/AN/A$1.07 per share2.12HYPRHyperfine$12.89M4.22N/AN/A$0.67 per share1.04LYRALyra Therapeutics$1.53M9.28N/AN/A$8.86 per share1.21SURGSurgePays$60.88M0.94N/AN/A$0.76 per share3.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AHYPRHyperfine-$40.72M-$0.54N/AN/AN/A-343.42%-74.19%-62.40%8/6/2025 (Estimated)LYRALyra Therapeutics-$93.43M-$60.50N/AN/AN/A-6,711.39%-295.52%-66.95%8/12/2025 (Estimated)SURGSurgePays-$45.73M-$2.79N/AN/AN/A-136.37%-206.01%-153.67%8/12/2025 (Estimated)Latest LYRA, HYPR, SURG, and CTCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025HYPRHyperfine-$0.12-$0.12N/A-$0.12$2.82 million$2.14 million5/13/2025Q1 2025SURGSurgePays-$0.40-$0.38+$0.02-$0.38$9.80 million$10.58 million5/6/2025Q1 2025LYRALyra Therapeutics-$7.50-$6.00+$1.50-$0.13$0.16 million$0.18 million3/25/2025Q4 2024SURGSurgePays-$0.27-$0.93-$0.66-$1.02$8.22 million$9.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/ASURGSurgePaysN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29HYPRHyperfineN/A6.075.48LYRALyra TherapeuticsN/A2.962.96SURGSurgePays0.241.721.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%HYPRHyperfine15.03%LYRALyra Therapeutics95.62%SURGSurgePays6.94%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%HYPRHyperfine30.98%LYRALyra Therapeutics3.25%SURGSurgePays30.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableHYPRHyperfine19077.83 million53.72 millionOptionableLYRALyra Therapeutics501.33 million1.28 millionOptionableSURGSurgePays4020.41 million14.19 millionOptionableLYRA, HYPR, SURG, and CTCX HeadlinesRecent News About These CompaniesSurgePays (NASDAQ:SURG) Price Target Raised to $9.00 at Ascendiant Capital MarketsJune 18 at 1:23 AM | americanbankingnews.comSurgePays (NASDAQ:SURG) Price Target Raised to $9.00June 16 at 8:17 AM | marketbeat.comSurgePays to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 24-25June 11, 2025 | prnewswire.comSurgePays, Inc. (NASDAQ:SURG) Sees Significant Decrease in Short InterestJune 4, 2025 | marketbeat.comSurgePays (NASDAQ:SURG) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?May 31, 2025 | marketbeat.comSurgePays (NASDAQ:SURG) Upgraded by Wall Street Zen to Hold RatingMay 24, 2025 | marketbeat.comSurgePays Confirms Directors and Ratifies Accounting FirmMay 20, 2025 | tipranks.comAT&T (NYSE:T) Partners With Carbyne For APEX Continuity Emergency Solution For PSAPsMay 20, 2025 | finance.yahoo.comUS$8.75 - That's What Analysts Think SurgePays, Inc. (NASDAQ:SURG) Is Worth After These ResultsMay 17, 2025 | uk.finance.yahoo.comSurgePays Secures $7M Convertible Note for ExpansionMay 16, 2025 | tipranks.comWhy SurgePays, Inc.’s (SURG) Stock Is Down 19.64%May 15, 2025 | aaii.comQ1 2025 Surgepays Inc Earnings CallMay 15, 2025 | uk.finance.yahoo.comSurgePays, Inc. (SURG) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comSurgePays, Inc. (SURG) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comSurgePays Reports First Quarter 2025 Financial ResultsMay 13, 2025 | prnewswire.comSurgePays Announces $7 Million Debt Financing to Accelerate GrowthMay 13, 2025 | prnewswire.comSurgePays to Host First Quarter 2025 Financial Results Conference Call on Tuesday, May 13thMay 6, 2025 | prnewswire.comEarnings Preview: SurgePays, Inc. (SURG) Q1 Earnings Expected to DeclineMay 5, 2025 | zacks.comPOS Fintech SurgePays Launches on AT&TApril 28, 2025 | crowdfundinsider.comSurgePays Launches Nationwide on AT&T Network with 250,000 SIMs ShippedApril 24, 2025 | prnewswire.comSurgePays Promotes Derron Winfrey to President, Sales and OperationsApril 23, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsMercadoLibre Is Soaring—Should You Wait for a Better Entry?By Ryan Hasson | May 26, 2025View MercadoLibre Is Soaring—Should You Wait for a Better Entry?Applied Digital's Strategic AI Play Gains MomentumBy Jeffrey Neal Johnson | May 21, 2025View Applied Digital's Strategic AI Play Gains Momentum$30B AI Opportunity: Will It Power Meta’s Next Surge?By Leo Miller | May 21, 2025View $30B AI Opportunity: Will It Power Meta’s Next Surge?Silver's Options Sizzle: Are Traders Betting on a Breakout?By Jeffrey Neal Johnson | June 5, 2025View Silver's Options Sizzle: Are Traders Betting on a Breakout?LYRA, HYPR, SURG, and CTCX Company DescriptionsCarmell NASDAQ:CTCX$2.27 -0.16 (-6.58%) As of 06/17/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Hyperfine NASDAQ:HYPR$0.70 0.00 (-0.11%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.70 +0.00 (+0.11%) As of 06/18/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.Lyra Therapeutics NASDAQ:LYRA$10.68 +0.40 (+3.89%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$10.81 +0.13 (+1.25%) As of 06/18/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.SurgePays NASDAQ:SURG$2.81 +0.12 (+4.46%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.73 -0.08 (-2.70%) As of 06/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SurgePays, Inc., together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities. SurgePays, Inc. is headquartered in Bartlett, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
